Oncolytics Biotech Files March 2024 6-K Report
Ticker: ONCY · Form: 6-K · Filed: Mar 4, 2024 · CIK: 1129928
| Field | Detail |
|---|---|
| Company | Oncolytics Biotech INC (ONCY) |
| Form Type | 6-K |
| Filed Date | Mar 4, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-K, foreign-private-issuer
Related Tickers: ONC
TL;DR
ONCOLYTICS BIOTECH (ONC) filed its March 6-K, confirming foreign private issuer status and 20-F reporting.
AI Summary
Oncolytics Biotech Inc. filed a Form 6-K on March 4, 2024, reporting as a foreign private issuer. The filing indicates the company is submitting its report for the month of March 2024 and is required to file annual reports under Form 20-F. The company's principal executive offices are located in Calgary, Alberta, Canada.
Why It Matters
This filing provides routine updates for investors and regulatory bodies regarding Oncolytics Biotech Inc.'s status as a foreign private issuer.
Risk Assessment
Risk Level: low — This is a routine administrative filing for a foreign private issuer and does not contain material new financial or operational information.
Key Players & Entities
- ONCOLYTICS BIOTECH INC (company) — Filer of the 6-K report
- March 4, 2024 (date) — Filing date of the report
- Calgary, Alberta, Canada (location) — Location of principal executive offices
- Form 6-K (document) — Type of SEC filing
- Form 20-F (document) — Annual report form required by the company
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report information as a foreign private issuer for the month of March 2024.
Which annual report form is Oncolytics Biotech Inc. required to file?
Oncolytics Biotech Inc. is required to file its annual reports under cover of Form 20-F.
Where are Oncolytics Biotech Inc.'s principal executive offices located?
Oncolytics Biotech Inc.'s principal executive offices are located at Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5.
What is the SEC file number for Oncolytics Biotech Inc.?
The SEC file number for Oncolytics Biotech Inc. is 001-38512.
Does this filing indicate submission in paper format?
The filing includes checkboxes for submitting Form 6-K in paper, but it is not indicated as submitted in paper in this excerpt.
Filing Stats: 334 words · 1 min read · ~1 pages · Grade level 17 · Accepted 2024-03-04 12:37:31
Filing Documents
- form6kq42023call.htm (6-K) — 18KB
- oncyq42023call.htm (EX-99.1) — 11KB
- 0001129928-24-000010.txt ( ) — 30KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date March 4, 2024 Kirk Look Chief Financial Officer